Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Spruce Biosciences reported Q1 financial results, highlighting a strengthened balance sheet with $69.0 million in gross proceeds from a recent public offering and a $50.0 million term loan facility with Avenue Capital. The company stated its cash runway now extends into the second half of 2027, supporting operations through the planned BLA submission for TA-ERT in Q4 2026 and potential U.S. commercial launch in 2027.
Key figures
- Guidance
- Cash runway into the second half of 2027
- Deal Value Usd
- 69000000
- Offering Price
- 50
- Shares Offered
- 1150000
- Atm facility
- 75000000
- Cash q1 2026
- 54080000
- Net loss q1 2026
- 12266000
- Cash april 30 2026
- 107300000
- Term loan facility
- 50000000
- Ga expenses q1 2026
- 4412000
- Rd expenses q1 2026
- 7575000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.